In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice

被引:18
作者
Le Goff-Klein, N [1 ]
Koffel, JC [1 ]
Jung, L [1 ]
Ubeaud, G [1 ]
机构
[1] Fac Pharm, Chim Therapeut Lab, F-67401 Illkirch Graffenstaden, France
关键词
simvastatin; grapefruit juice; naringenin; bergamottin; CYP; 450; metabolism; inhibition;
D O I
10.1016/S0928-0987(02)00222-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Grapefruit juice is responsible for many drug interactions but the exact components involved in this interaction are not precisely known. Flavonoids and furocoumarin derivatives such as naringenin and bergamottin, respectively, could be involved in the inhibition of drug metabolism. The objective of this paper is to investigate in vitro the possible metabolic hepatic interaction between simvastatin (SV) and bergamottin (BG) and thus-to compare its effects to those of naringenin (NRG) the aglycone form of naringin (NR) (a flavonoid present in grapefruit juice). In human and rat microsomes and in rat hepatocytes, BG was found to be a mixed type inhibitor of SV metabolism. In rat liver microsomes the K-i value of BG (K-i = 174 +/- 36 muM) is higher than the K, value of NRG (K-i = 29 +/- muM). However, in human liver microsomes the K-i values are similar in BG and NRG (K-i = 34 +/- 5 muM and 29 +/- 11 muM, respectively). Moreover, it seems that there is an interspecies difference between human and rat hepatic metabolism of SV involving different isoenzymes of CYP 450. In conclusion, our study shows that BG inhibits SV metabolism. BG and NRG could therefore be applied as markers in food-drug interaction studies in order to adjust posology. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 24 条
  • [1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT
    ALBERTS, AW
    CHEN, J
    KURON, G
    HUNT, V
    HUFF, J
    HOFFMAN, C
    ROTHROCK, J
    LOPEZ, M
    JOSHUA, H
    HARRIS, E
    PATCHETT, A
    MONAGHAN, R
    CURRIE, S
    STAPLEY, E
    ALBERSSCHONBERG, G
    HENSENS, O
    HIRSHFIELD, J
    HOOGSTEEN, K
    LIESCH, J
    SPRINGER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07): : 3957 - 3961
  • [2] Grapefruit juice-drug interactions
    Bailey, DG
    Malcolm, J
    Arnold, O
    Spence, JD
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) : 101 - 110
  • [3] Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram
    Benton, RE
    Honig, PK
    Zamani, K
    Cantilena, LR
    Woosley, RL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) : 383 - 388
  • [4] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [5] Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
  • [6] CONDORCET D, 1996, TRANSFORMATION ESTIM
  • [7] The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: The role of gut CYP3A and P-glycoprotein
    Di Marco, MP
    Edwards, DJ
    Wainer, IW
    Ducharme, MP
    [J]. LIFE SCIENCES, 2002, 71 (10) : 1149 - 1160
  • [8] INHIBITORY EFFECT OF GRAPEFRUIT JUICE AND ITS BITTER PRINCIPAL, NARINGENIN, ON CYP1A2 DEPENDENT METABOLISM OF CAFFEINE IN MAN
    FUHR, U
    KLITTICH, K
    STAIB, AH
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (04) : 431 - 436
  • [9] Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction
    Fukuda, K
    Guo, LQ
    Ohashi, N
    Yoshikawa, M
    Yamazoe, Y
    [J]. JOURNAL OF CHROMATOGRAPHY B, 2000, 741 (02): : 195 - 203
  • [10] Ho P C, 2000, Pharm Acta Helv, V74, P379